[e-drug] KEI roundtable on manufacturing capacity for COVID-19 vaccines

E-DRUG: KEI roundtable on manufacturing capacity for COVID-19 vaccines
--------------------------------------------------------------------------

KEI roundtable on pathways to scale up manufacturing capacity for COVID-19
vaccines

Friday, 19 February 2021
14h00 UTC to 16h00 UTC
15h00 CET to 17h00 CET

On Friday, 19 February 2021, KEI will host a virtual roundtable to discuss
pathways to scale production, increase competition and speed the delivery
of COVID-19 vaccines. This roundtable will provide experts and policymakers
the opportunity to exchange views on the challenges and opportunities to
scale production of COVID-19 vaccines. This dialogue will encourage experts
to address practical issues for the transfer of know-how and technology for
manufacturing.

To register:
vaccine-roundtable@keionline.org

Questions and topics to be raised include:

   - Which vaccines represent the most significant opportunities in terms
   of scaling manufacturing capacity and enhancing access?
   - What incentives, mandates and/or subsidies are useful in expanding
   access to vaccine manufacturing know-how and capacity?
   - What is currently known about global manufacturing capacity for each
   relevant COVID-19 vaccine, and what measures are necessary to bring a
   facility into good manufacturing practice compliance for production of
   specific vaccines and other COVID-19 health technologies?
   - What is the WHO prequalification program doing regarding COVID-19
   vaccines?
   - What is the WHO C-TAP doing to expand manufacturing for COVID-19
   vaccines?
   - What is the Medicines Patent Pool doing to expand manufacturing for
   COVID-19 vaccines?
   - What are national governments doing to scale and expand vaccine
   manufacturing access?
   - What mistakes were made in 2020, and what mistakes need to be avoided
   in 2021?

Thiru Balasubramaniam
Knowledge Ecology International
Geneva
<thiru@keionline.org>